ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.

Test & Measurement

Health Care

Biotechnology

REPROCELL

Chikafumi Yokoyama

Allison Francis

Litong Liu

Karen Bingham

Yasuyuki Asai

Chirag Tawde

Graeme Macluskie

Ejaz Ansari

David Bunton

Rama Modali

Yoshiyuki Yamakawa

Daisuke Usui

The Quality Assurance Team at ReproCELL ensures that all stem cell technologies and clinical testing services meet rigorous compliance and quality standards. They oversee the validation of research reagents and materials, implement quality control processes, and conduct audits to maintain the integrity of products used in regenerative medicine and transplantation. By safeguarding the quality and reliability of their offerings, the team supports ReproCELL's commitment to advancing stem cell research and therapeutic applications.

Quality Assurance Team

Research and Development

Sales and Marketing

Leadership Team

Quality Assurance Team

About

Team members

Other teams at REPROCELL

Research and Development

Sales and Marketing

Leadership Team